Latest Antivirals Stories
EDISON, N.J., Oct. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc.
Proceeds to Fund Phase 2b Study of FV-100 Fast-Acting Oral Antiviral EDISON, N.J., Oct. 15, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc.
Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct.
MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression,
~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and
FLINT, Mich., Sept.
EDISON, N.J., Sept. 3, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc.
- Emitting flashes of light; glittering.